உலகளாவிய தலை ஆஃப் ஆராய்ச்சி வளர்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உலகளாவிய தலை ஆஃப் ஆராய்ச்சி வளர்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உலகளாவிய தலை ஆஃப் ஆராய்ச்சி வளர்ச்சி Today - Breaking & Trending Today

Johnson & Johnson Vision Announces FDA Approval of ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management

/PRNewswire/ Johnson & Johnson Vision , a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies†, today announced that the. ....

Moshe Mendelson , Global Head Of Research Development , Drug Administration , Johnson Vision Care Inc , Lions Clubs International Foundation , Johnson Medical Devices Companies , Johnson Surgical Vision Inc , Johnson Vision Inc , Xiao Yu Song , Global Head , Overnight Therapeutic Lenses , Johnson Vision , Overnight Therapeutic , Myopia Management , Safety Information , Contact Lens , Johnson Surgical Vision , Johnson Vision Care , Medical Devices , Surgical Vision , Vision Care , Myopia Onset , High Myopia , Year Follow Up , Temporal Trends , Eye Contact ,

Sanofi SA (SNY) Q1 2021 Earnings Call Transcript

Sanofi SA (SNY) Q1 2021 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Sanofi SA (NASDAQ: SNY)
[Audio begins abruptly] Sanofi s First Quarter 2021 Earnings Call.
I would now like to turn the call over to Eva Schaefer-Jansen, Head of Sanofi Investor Relations. Please go ahead, Eva.SPONSORED:
10 stocks we like better than Sanofi
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,
Motley Fool Stock Advisor, has tripled the market.
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now. and Sanofi wasn t one of them! That s right they think these 10 stocks are even better buys. ....

Thomas Triomphe , Sanofi Pasteur , Paul Hudson , Geoffrey Porges Leerink Swann , Julie Van Ongevalle , Mather Simon Exane , Eva Schaefer Jansen , Olivier Charmeil , America Merrill Lynch , Daiichi Sankyo , Pete Verdult , John Reed , Enregistrement Universel , Sanofi Genzyme , Peter Verdult Citigroup , Dupixent Nbrx , Global Head Of Research Development , Jp Morgan , Sanofi Global Health , Credit Suisse , Graham Parry Bank , Motley Fool Sanofi , Call Transcript , Motley Fool Logo , First Quarter , Sanofi Investor ,

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi's novel investigational IL-2

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi s novel investigational IL-2
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi s novel investigational IL-2
Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1
THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi s Synthorin technology platform, is being studied in a trial of adults with advanced or metastatic solid tumors
PARIS - April 9, 2021 - Interim data from a first-in-human trial evaluating the safety, therapeutic activity and maximum tolerable dose of THOR-707 (SAR444245), a highly differentiated not-alpha interleukin-2 (IL-2) candidate, as a monotherapy and in combination with anti-PD-1, will be presented Saturday, April 10 as a l ....

United States , France General , Eva Schaefer Jansen , Arnaud Delepine , Suzanne Greco , Felix Lauscher , Sanofi Synthorin , John Reed , Filip Janku , Fara Berkowitz , Sally Bain , Division Of Cancer Medicine , Global Head Of Research Development , American Association For Cancer Research , University Of Texas Md Anderson Cancer Center , Merck Co , Department Of Investigational Cancer Therapeutics , American Association , Cancer Research , Global Head , Natural Killer , Associate Professor , Investigational Cancer Therapeutics , Cancer Medicine , Cancer Center , Expanded Genetic Alphabet ,

Viatris Inc. Hosts Inaugural Investor Day Outlining Unique and Differentiated Business Model, High-Quality Operational Platform, and Focus on CSR and Financial Commitments

Share this article
Share this article
PITTSBURGH, March 1, 2021 /PRNewswire/ At a virtual meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS) will outline how the company expects to lead as a new kind of healthcare company with a unique and differentiated business model, high-quality operational platform and clear focus on ensuring its sustainability priorities and financial commitments are met.
Viatris CEO Michael Goettler said, Building on a strong, combined foundation, we are embarking on a multi-year journey to transform our company. We believe that we are well positioned to achieve our goals by leveraging our strengths and unique capabilities. We are relentless in our commitment to continuous improvement and high quality. Our obsession to create value in everything we do will serve as our north star. With talented and committed colleagues, an engaged culture and clear strategy, we are confident we can deliver enhanced shareholder value ....

United States , New Zealand , Andhra Pradesh , Tony Mauro , Sanjeev Narula , Rajiv Malik , Menassie Taddese , Michael Goettler , Lara Ramsburg , Sanjeev Sethi , Walt Owens , Global Head Of Research Development , Head Of Corporate Affairs , Viatris Inc , Global Healthcare , Corporate Social Responsibility , Chief Executive Officer , Chief Financial Officer , Developed Markets , Emerging Markets , Greater China Region , Chief Operating Officer , Global Head , Corporate Affairs , Viatris Investor Day , Investor Day ,

Sanofi (SNY) Q4 2020 Earnings Call Transcript

Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi Fourth Quarter 2020 Earnings Call and Virtual Capital Markets Day. We have planned for a 15-minute break between both events. You may remain connected to the Zoom link for all sessions.
I would now like to turn the call over to Eva Schaefer-Jansen, Head of Sanofi Investor Relations. Please go ahead, Eva.
Eva Schaefer-Jansen
Head of Investor Relations
Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi s 2020 fourth quarter results, followed by a dedicated Q&A session. In about an hour, we will begin our virtual Capital Markets Day presentation and discussion. As usual, you can find the slides to both sessions on the Investors page of our website at sanofi.com. ....

France General , United States , Societe Generale , Thomas Triomphe , Florent Cespedes , Sanofi Pasteur , Paul Hudson , Flubok Supemtek , Julie Van Ongevalle , Wimal Kapadia , Eva Schaefer Jansen , Olivier Charmeil , America Merrill Lynch , Pete Verdult , John Reed , Enregistrement Universel , Sanofi Genzyme , Peter Verdult Citigroup , Jo Walton , Richard Vosser , Geoff Porges , Wimal Kapadia Bernstein , Digestive Health , Global Head Of Research Development , Graham Parry Bank , Garnier Co Analyst ,